Trial Profile
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Ontamalimab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms CARMEN CD 305
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 10 Feb 2021 This trial has been completed in Poland.
- 18 Jan 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record. (Global end date: 2020-10-08)
- 24 Dec 2020 This trial has been completed in Croatia, according to European Clinical Trials Database record.